Markets:

Overview

News

Currencies

International

Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

23.18 +0.16 (+0.70%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Pacira BioSciences, Inc. - Common Stock

TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday ↗

January 10, 2025

Via Benzinga

Pacira BioSciences Secures FDA Approval For New iovera SmartTip to Manage Chronic Low Back Pain ↗

January 07, 2025

Pacira launches a new iovera° Smart Tip for chronic back pain relief, offering an alternative to radiofrequency ablation with promising study results.

Via Benzinga

Investors seeking growth at a reasonable cost should explore NASDAQ:PCRX. ↗

December 12, 2024

Investors should take note ofPACIRA BIOSCIENCES INC (NASDAQ:PCRX), a growth stock that remains attractively priced.

Via Chartmill

Expert Ratings For Pacira BioSciences ↗

September 24, 2024

Via Benzinga

Pain Management-Focused Pacira BioSciences Loses Patent Fight For Key Drug, JP Morgan Analyst Downgrades On Unclear Path ↗

August 12, 2024

Pacira BioSciences faces a significant setback as the U.S. District Court invalidates its key patent on Exparel, leading to a 40% stock drop. Exparel, crucial to Pacira's revenue, is now vulnerable,...

Via Benzinga

Topics Intellectual Property

Where Pacira BioSciences Stands With Analysts ↗

August 12, 2024

Via Benzinga

Expert Ratings For Pacira BioSciences ↗

July 25, 2024

Via Benzinga

NASDAQ:PCRX: good value for what you're paying. ↗

June 26, 2024

For those who appreciate value investing, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is a compelling option with its solid fundamentals.

Via Chartmill

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

For those who appreciate value investing, NASDAQ:PCRX is a compelling option with its solid fundamentals. ↗

February 25, 2025

PACIRA BIOSCIENCES INC has a stellar value proposition. NASDAQ:PCRX not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point.

Via Chartmill

Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate ↗

February 14, 2025

Virpax completed a U.S. Army-backed Probudur study, showing potential for prolonged pain relief and reduced opioid use in surgical recovery.

Via Benzinga

Despite its impressive fundamentals, NASDAQ:PCRX remains undervalued. ↗

February 03, 2025

Consider PACIRA BIOSCIENCES INC as a top value stock. NASDAQ:PCRX shines in terms of profitability, solvency, and liquidity, all while remaining very reasonably priced.

Via Chartmill

What 8 Analyst Ratings Have To Say About Pacira BioSciences ↗

January 30, 2025

Via Benzinga

6 Analysts Assess Pacira BioSciences: What You Need To Know ↗

January 13, 2025

Via Benzinga

NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

January 13, 2025

PACIRA BIOSCIENCES INC (NASDAQ:PCRX), an undervalued stock with good fundamentals.

Via Chartmill

Decoding 6 Analyst Evaluations For Pacira BioSciences ↗

December 04, 2024

Via Benzinga

Evaluating Pacira BioSciences: Insights From 8 Financial Analysts ↗

November 07, 2024

Via Benzinga

Insights into Pacira BioSciences's Upcoming Earnings ↗

November 05, 2024

Via Benzinga

JetBlue Airways, B. Riley Financial, Hawaiian Electric And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

August 12, 2024

Via Benzinga

NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

August 08, 2024

In a market where value is scarce, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) offers a refreshing opportunity with its solid fundamentals.

Via Chartmill

PCRX Stock Earnings: Pacira BioSciences Beats EPS, Beats Revenue for Q2 2024 ↗

July 30, 2024

PCRX stock results show that Pacira BioSciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

3 Biotech Stocks to Buy on the Dip: July 2024 ↗

July 29, 2024

Biotech stocks are critically important to the broader market. However, it might make more sense to consider buying on the dip.

Via InvestorPlace

In a market where value is scarce, NASDAQ:PCRX offers a refreshing opportunity with its solid fundamentals. ↗

July 17, 2024

PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is probably undervalued for the fundamentals it is displaying.

Via Chartmill

Top 5 Health Care Stocks That May Explode In July ↗

July 08, 2024

Via Benzinga

NASDAQ:PCRX, an undervalued stock with good fundamentals. ↗

June 05, 2024

Despite its impressive fundamentals, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) remains undervalued.

Via Chartmill

Analyst Ratings For Pacira BioSciences ↗

May 08, 2024

Via Benzinga

This Charter Communications Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday ↗

July 03, 2024

Via Benzinga

Peeling Back The Layers: Exploring Pacira BioSciences Through Analyst Insights ↗

July 02, 2024

Via Benzinga

When you look at NASDAQ:PCRX, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗

May 15, 2024

When you look at PACIRA BIOSCIENCES INC (NASDAQ:PCRX), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

Via Chartmill

PCRX Stock Earnings: Pacira BioSciences Meets EPS, Beats Revenue for Q1 2024 ↗

May 07, 2024

PCRX stock results show that Pacira BioSciences met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Via InvestorPlace

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

Headline News about Pacira BioSciences, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today